Quarterly report pursuant to Section 13 or 15(d)

Long-Term Debt and Other Financings - Novartis Note (Details)

v3.21.2
Long-Term Debt and Other Financings - Novartis Note (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 21, 2020
Jun. 30, 2021
May 31, 2005
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2017
Dec. 31, 2015
Dec. 31, 2020
Sep. 30, 2015
Long-term debt                      
Revenue from contracts with customers       $ 525 $ 53 $ 544 $ 553        
Loss on extinguishment of debt       (300)   (300)          
Novartis Note                      
Long-term debt                      
Research and development expenses funded through loan facility, maximum (as a percent)     75.00%                
Maximum borrowing capacity under loan agreement     $ 50,000                
Amount by which note will be reduced upon achievement of specified milestones                     $ 7,300
Reduction in debt obligation $ 7,300 $ 9,100                  
Debt amount   $ 0   0   0       $ 9,100  
Loss on extinguishment of debt           0          
Novartis Note | Six-month LIBOR                      
Long-term debt                      
Basis spread on variable rate     2.00%                
Novartis International | License Agreement                      
Long-term debt                      
Revenue from contracts with customers 25,000     $ 0 $ 0 $ 0 $ 0 $ 10,000 $ 37,000    
Cash payment received $ 17,700               $ 37,000